Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1726880 | 0.76 | OPRD1 (0.45) | ACHEESR1ESR2OPRD1 | |
| SCHEMBL4517111 | 0.76 | OPRD1 (0.45) | ACHEESR1ESR2OPRD1 | |
| SCHEMBL1726878 | 0.76 | OPRD1 (0.45) | ACHEESR1ESR2OPRD1 | |
| SCHEMBL11164638 | 0.76 | IGF1R (0.53) | ACHEIGF1RALOX15ADRA2AADRA2B | |
| SCHEMBL15109677 | 0.72 | ACHE (0.40) | ACHEOPRD1 | |
| SCHEMBL15109754 | 0.72 | HTR2A (0.41) | ACHEESR1ESR2OPRD1 | |
| SCHEMBL28170162 | 0.70 | ACHE (0.43) | ACHEADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL3535473 | 0.69 | KDM1A (0.45) | ACHEESR1ESR2 | |
| SCHEMBL2803692 | 0.69 | ACHE (0.51) | ACHEESR1ESR2 | |
| SCHEMBL8274690 | 0.69 | ESR1 (0.55) | ACHEESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | ACHE 1589/4885ESR1 1353/4885ESR2 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.